Hansa Biopharma AB (publ) - Special Call Transcript
Ladies and gentlemen, welcome to the Hansa Biopharma AB Investor Presentation. (Operator Instructions) This call is being recorded.
I'll now hand the word over to CEO, Søren Tulstrup. Please begin.
¸ - ()-&
Thank you, operator. Good morning, and welcome to the Hansa Biopharma conference call on the partnership agreement in gene therapy with Sarepta Therapeutics announced earlier today. I'm Søren Tulstrup, CEO of Hansa Biopharma. With me today, I have our Chief Scientific Officer and Chief Operating Officer, Christian Kjellman; and Chief Financial Officer, Donato Spota; as well as our Head of Investor Relations, Klaus Sindahl. Our presentation should take about 10 to 15 minutes. And after that, we'll take your questions.
Now please turn to Slide 2. Please allow me to draw your attention to our forward-looking statement, which applies to this presentation.
Please turn to Slide 3. On today's call, we'll go through
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |